Clinical Trials on Advanced Non-squamous Non-small-cell Lung Cancer

Total 7775 results

Memorial Sloan Kettering Cancer Center
AstraZeneca

Recruiting

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

NSCLC | Lung Cancer | Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | PD-L1 Gene Mutation | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage II

United States
Virginia Commonwealth University
National Cancer Institute (NCI)

Withdrawn

Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI); OSI Pharmaceuticals

Completed

Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer | Adenosquamous Cell Lung Cancer

United States
Hoffmann-La Roche

Completed

An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT) (ELEMENT)

Non-Squamous Non-Small Cell Lung Cancer

Serbia
Washington University School of Medicine
Arcus Biosciences, Inc.

Active, not recruiting

Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Carcinoma

United States
Advaxis, Inc.

Completed

Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

Lung Cancer, Non-Small Cell | Metastatic Squamous Cell Carcinoma | Metastatic Non-Squamous Cell Carcinoma

United States
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower130)

Carcinoma, Non-Squamous Non-Small Cell Lung

United States, Israel, Belgium, Canada, Spain, Germany, Italy, France
Bayer

Not yet recruiting

A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2)

Advanced Non-small Cell Lung Cancer | HER2 Mutation

United States, Korea, Republic of, Belgium, China, Japan, Taiwan, Denmark, Germany, Israel, Italy, United Kingdom, Bulgaria, Portugal, Switzerland, Greece, Turkey, Sweden, France, Singapore, Mexico, Spain, Netherlands, Poland, Brazil, A... and more
Hubei Cancer Hospital

Recruiting

Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy

Non Small Cell Lung Cancer | Radiotherapy | Immunotherapy | Locally Advanced

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China
Beijing Biostar Pharmaceuticals Co., Ltd.

Recruiting

Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Relapsed or Advanced Non-small Cell Lung Cancer
AstraZeneca
Daiichi Sankyo

Recruiting

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China, Korea, Republic of, Germany, Italy, Poland, Belgium, Mexico, Turkey, Spain, France, United States, Canada, Taiwan, Brazil, Austria, Hong Kong, India, Japan, Netherlands, Denmark
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043) (ALTER-L043)

Resectable Locally Advanced Non-small Cell Lung Cancer

China
AstraZeneca
Daiichi Sankyo

Recruiting

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (DL03)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Korea, Republic of, Italy, Poland, Malaysia, Taiwan, Thailand, United States, France, Netherlands, Philippines, Canada, Singapore, Spain, Turkey, Australia, Belgium, Israel
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Guangdong Provincial People's Hospital

Not yet recruiting

Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

Advanced Non-small Cell Lung Cancer

China
AstraZeneca
Parexel

Active, not recruiting

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY)

Advanced or Metastatic Non-Small Cell Lung Cancer

United States, France, Italy, Spain, Belgium, Romania, Canada, Korea, Republic of, Brazil, Hungary, Japan, China, Taiwan, Hong Kong, United Kingdom, Germany, Poland, Australia, Netherlands, Serbia, India, Argentina, Ireland
Institut Claudius Regaud
Merck KGaA, Darmstadt, Germany

Completed

Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer

Locally Advanced Non Small Cell Lung Cancer (NSCLC)

France
AstraZeneca

Terminated

Gefitinib Long-term Survivor Study

EGFR Mutation Positive Advanced Non-small-cell Lung Cancer

China
Taiho Oncology, Inc.

Completed

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

Advanced or Metastatic Non-small Cell Lung Cancer

United States, France, Poland, Spain, Italy, Japan
Swiss Group for Clinical Cancer Research

Completed

Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.

Lung Cancer | KRAS Gene Mutation | Advanced Non-small Cell Lung Cancer

Switzerland
OSI Pharmaceuticals

Completed

Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer | Failed Prior Chemotherapy

United States
Case Comprehensive Cancer Center

Terminated

Biofeedback Training in Patients With Advanced Lung Cancer - A Pilot Study

Advanced (Stage IV) Non-small Cell Lung Cancer (NSCLC)

United States
Ass. Prof. Jan Nyman

Terminated

Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis Treatment With Radiochemotherapy (PLANET)

Non Small Cell Lung Cancer | Locally Advanced Disease

Sweden
Hoffmann-La Roche

Withdrawn

A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease

Non-Squamous Non-Small Cell Lung Cancer
Genentech, Inc.
Hoffmann-La Roche

Completed

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Non-Squamous Non-Small Cell Lung Cancer

Poland, Belgium, Spain, United States, Canada, South Africa, Russian Federation, Hong Kong, Taiwan, Japan, France, United Kingdom, Australia, Germany, Hungary, Korea, Republic of, Netherlands, Croatia, Serbia, Israel, Ukraine, Peru, Brazi... and more
Hoffmann-La Roche

Completed

A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy

Non-Squamous Non-Small Cell Lung Cancer

China, Korea, Republic of, South Africa, Taiwan, Hungary, France, Netherlands, United States, Bulgaria, Slovakia, Canada, Italy, Brazil, Thailand, Romania, Lithuania, Poland, Latvia, Ukraine, Czech Republic
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery

Stage IIIA Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer | Adenosquamous Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

Canada
AbbVie

Active, not recruiting

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

Advanced Solid Tumors Cancer | Non Small Cell Lung Cancer (NSCLC)

United States, Australia, France, Israel, Japan, Korea, Republic of, Spain, Taiwan
Assistance Publique - Hôpitaux de Paris
Bristol-Myers Squibb

Terminated

Tumor Mutational Burden in Lung Cancer Patients (MUBULUC)

Non Small Cell Lung Cancer | Non-small Cell Lung Cancer Stage IV | Non Small Cell Lung Cancer Stage III | Non-Small Cell Carcinoma of Lung

France
National Cancer Institute (NCI)

Terminated

Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Soroka University Medical Center

Unknown

Valproic Acid With Chemoradiotherapy for Non-Small-Cell Lung Cancer

Locally Advanced Inoperable Non-small-lung Cancer

Israel
National Cancer Institute (NCI)

Completed

Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies

Non-Small-Cell Lung Carcinoma | Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura | Advanced Esophageal Cancers | Primary Small Cell Lung Cancers | Pleural Mesotheliomas

United States
Chao Huang
University of Kansas Medical Center

Active, not recruiting

Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy

Advanced Solid Tumor | Non-small Cell Lung Cancer (NSCLC)

United States
Jeffrey Clarke
Novartis Pharmaceuticals; NantCell, Inc.

Completed

A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007 (RAP)

Advanced Solid Tumors, Non-small Cell Lung Cancer

United States
Pfizer

Completed

Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer

Non Small Cell Lung Cancer | Advanced Solid Tumors

United States
Axelar AB

Completed

Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung

Non-small-cell Lung Cancer | Squamous Cell Carcinoma | Adenocarcinoma of the Lung

Russian Federation, Ukraine, Belarus, Hungary, Poland
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Completed

Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs

Advanced Stage Non-small Cell Lung Cancer

United States
TheraOp
AstraZeneca

Active, not recruiting

PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC (PACCELIO)

Stage III Non-small Cell Lung Cancer | Locally Advanced | Unresectable

Switzerland
Istituto Oncologico Veneto IRCCS
Ministry of Health, Italy

Completed

Individualized Treatment of Patients With Advanced NSCLC: Potential Application for Circulating Tumor Cells (CTC) Molecular and Phenotypical Profiling (2012/52)

Advanced Non Small Cell Lung Cancer

Italy
National Cancer Institute (NCI)

Completed

FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Recurrent Non-Small Cell Lung Carcinoma | Adenosquamous Lung Carcinoma | Bronchioloalveolar Carcinoma | Large Cell Lung Carcinoma | Squamous Cell Lung Carcinoma | Non-Small Cell Lung Carcinoma

United States, Canada, Israel
University Hospital, Angers
University Hospital, Rouen; Central Hospital, Nancy, France; University Hospital... and other collaborators

Unknown

Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient (FLT-THERA)

Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent | No EGFR Activating Mutation

France
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Metastatic NSCLC | Recurrent NSCLC | Advanced Non-Small Cell Squamous Lung Cancer

China
Mayo Clinic
National Cancer Institute (NCI)

Completed

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Extensive Stage Small Cell Lung Carcinoma | Squamous Cell Lung Carcinoma | Recurrent Small Cell Lung Carcinoma

United States
Nasser Hanna, M.D.
Bristol-Myers Squibb; Hoosier Cancer Research Network

Terminated

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

United States
Criterium, Inc.
EMD Serono Research & Development Institute, Inc.

Terminated

CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC

Advanced Non-Small Cell Lung Cancer With MET Mutations

United States
Fujian Cancer Hospital

Enrolling by invitation

Tislelizumab as Cross-line Treatment for Advanced NSCLC

Advanced Non-small-cell Lung Cancer

China
Roswell Park Cancer Institute

Completed

Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Emory University
Washington University Siteman Cancer Center

Active, not recruiting

An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

United States

Clinical Trials on Advanced Non-squamous Non-small-cell Lung Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations